CS
EW icon

Cannell & Spears’s Edwards Lifesciences EW Stock Holding History

Cannell & Spears’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,067
Closed -$243K – 213
2022
Q1 		$243K Hold
2,067
– – 0.02% 199
2021
Q4 		$268K Buy
+2,067
New +$241K 0.02% 196

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cannell & Spears's EW Position: Q2 2022 in Review

Cannell & Spears sold out of Edwards Lifesciences (EW) in Q2 2022, closing a stake of 2,067 shares — an estimated $243K sold.

Cannell & Spears first reported a position in EW in Q4 2021 and held it in 2 quarters. The position peaked at $268K in Q4 2021. 1,272 funds tracked by Wall St. Rank hold EW as of Q2 2022.

  • Cannell & Spears reported no remaining Edwards Lifesciences position as of Q2 2022 after selling out during the quarter.
  • Cannell & Spears sold 2,067 Edwards Lifesciences shares in Q2 2022, an estimated $243K.
  • Cannell & Spears first reported a position in Edwards Lifesciences in Q4 2021 and held it in 2 quarters.
  • Cannell & Spears's Edwards Lifesciences position peaked at $268K in Q4 2021.
  • 1,272 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2022.

Based on Cannell & Spears's 13F filing for Q2 2022, filed 8 Aug 2022.